Investing
Popular Now
Latest Posts
More Articles
Virtus KAR Mid-Cap Core Q4 2025 Review (VIMCX)
Performance Overview The Virtus KAR Mid-Cap Core Fund (VIMCX), specifically the Class I shares, recorded a return of -2.44% over
Should Investors Rush into Venture Capital Trusts Now?
Individuals looking to invest in venture-capital trusts before the tax year concludes might need to act swiftly. Numerous well-regarded funds
Baidu’s AI Momentum Thrives, But Search Lags Behind
Summary Baidu’s primary search operations are encountering significant structural obstacles, including flat monthly active user numbers and a consistent drop
Allspring International Equity: Q4 2025 Top Performers & Laggards
Fund Performance Overview The Allspring International Equity Fund delivered impressive results in the fourth quarter of 2025, surpassing its benchmark,
Teradata Poised for AI-Driven Growth Upside
The stock price of Teradata (NYSE: TDC) has experienced a significant rally over recent months, propelled by promising AI-driven opportunities.
Nvidia Set for Another Earnings Double Beat Preview
Nvidia Corporation’s shares have experienced a period of consolidation since the beginning of August 2025, displaying essentially flat performance throughout
Royal Bank of Canada Stock: Strong Franchise but Overvalued
Canadians have long appreciated their major banking institutions for compelling reasons that extend well beyond simple familiarity. The leading six banks operating across the country have built a consistent track record of raising dividend distributions to investors year after year. Historical perfo
IonQ, Rigetti, D-Wave Insiders Sell $615M in Quantum Stocks Warning
Quantum Computing Captures Wall Street’s Attention The individuals with the deepest insights into IonQ, Rigetti Computing, and D-Wave Quantum are
RBB Bancorp Demonstrates Strong Growth Potential
RBB Bancorp stands out as a compelling investment opportunity in the banking sector, backed by impressive loan expansion, strategic growth into Northern California markets, and a valuation that trades at an 11 percent discount relative to forward earnings multiples. Analysts maintain a Buy rating on
Vertex Pharmaceuticals: Resilient Biotech for Any Market Downturn
Vertex Pharmaceuticals possesses the financial strength and revenue potential to thrive regardless of prevailing market conditions. Although Vertex Pharmaceuticals (NASDAQ:
ASML Stock Drops 18% Amid July AI Market Volatility
What Happened with ASMLShares of ASML experienced a notable decline throughout July as broader market pressures weighed on artificial intelligence related equities and the firm released its second quarter financial results. Although the earnings report initially provided some upward movement, it pro
Gold Rally Outpaces Stocks: 2026 Forecast
Gold Crushed Stocks This Year. Could the Rally Continue in 2026? Over the past 50 years, the stock market has